Impact of the COVID-19 pandemic in the lipid control of the patients that start PCSK9 inhibitors
Article
Published on
Journal: Clínica e investigación en arteriosclerosis : publicación oficial de la
[Category] 임상,
Journal: Clínica e investigación en arteriosclerosis : publicación oficial de la
[Category] 임상,
[키워드] adverse event
Analysis
baseline value
cardiovascular disease
changes in
Clinical practice
clinical trials
Cognitive function
Colesterol-LDL
COVID-19
COVID-19 pandemic
Effectiveness
effectiveness-safety
Eficacia-seguridad
flu-like symptom
Follow-up
Impact
Inhibidores de la PCSK9
inhibitor
inhibitors
injection
intensity
LDL cholesterol
LDL-cholesterol
material
myalgia
not affected
not significant
pandemic
Patient
patients treated
PCSK9
PCSK9 inhibitors.
Pharmacist
reduction
statin
the patient
the primary endpoint
treated
was reduced
worsening
[DOI] 10.1016/j.arteri.2022.01.003 PMC 바로가기 [Article Type] Article
[DOI] 10.1016/j.arteri.2022.01.003 PMC 바로가기 [Article Type] Article